Search results for "Protective Agent"

showing 10 items of 226 documents

Protection of Flupirtine on β-Amyloid-Induced Apoptosis in Neuronal Cells In Vitro: Prevention of Amyloid-Induced Glutathione Depletion

2002

Effective drugs are not available to protect against beta-amyloid peptide (A beta)-induced neurotoxicity. Cortical neurons from rat embryos were treated with the toxic fragment A beta25-35 at 1 microM in the presence or absence of flupirtine, a triaminopyridine, successfully applied clinically as a nonopiate analgesic drug. Five days later 1 microM A beta25-35 caused reduction of cell viability to 31.1%. Preincubation of cells with flupirtine (1 or 5 microg/ml) resulted in a significant increase of the percentage of viable cells (74.6 and 65.4%, respectively). During incubation with A beta25-35 the neurons undergo apoptosis as determined by appearance of the characteristic stepladder-like D…

Pathologymedicine.medical_specialtyCell SurvivalAminopyridinesApoptosisPharmacologymedicine.disease_causeBiochemistryAntioxidantsCellular and Molecular NeurosciencemedicineAnimalsViability assaySenile plaquesRats WistarCerebral CortexNeuronsAmyloid beta-PeptidesChemistryNeurotoxicitymedicine.diseaseGlutathionePeptide FragmentsRatsOxidative StressNeuroprotective AgentsApoptosisCell cultureDNA fragmentationFlupirtineOxidative stressmedicine.drugJournal of Neurochemistry
researchProduct

Neuroprotective effect of flupirtine in prion disease

2003

Apoptotic neuronal cell death is a hallmark of prion diseases. The apoptotic process in neuronal cells is thought to be caused by the scrapie prion protein, PrPSc, and can be experimentally induced by its peptide fragment, PrP106-126. This process is a target for potential drugs to combat prion disease or to ameliorate its symptoms. Flupirtine (Katadolon), a pyridine derivative that is in clinical use as a nonopioid analgesic, has a potent cytoprotective effect, at concentrations above 1 microg/mL, on neuronal cells treated with PrP(Sc) or PrP106-126. This drug acts as an N-methyl-D-aspartate (NMDA) antagonist, but does not bind to NMDA receptors. Flupirtine normalizes the level of intracel…

Pathologymedicine.medical_specialtyProgrammed cell deathanimal diseasesAnalgesicAminopyridinesScrapiePharmacologyNeuroprotectionPrion DiseasesmedicineAnimalsHumansPharmacology (medical)Pharmacologybusiness.industryAntagonistGeneral MedicineGlutathioneGenes bcl-2nervous system diseasesNeuroprotective Agentsnervous systemApoptosisNMDA receptorCalciumFlupirtinebusinessmedicine.drugDrugs of Today
researchProduct

Erythropoietin and subarachnoid hemorrhage.

2010

Pathologymedicine.medical_specialtySubarachnoid hemorrhageErytTime Factorserythropoietin subarachnoid hemorragelaw.inventionAnimals; Brain Ischemia; Clinical Trials; Phase II as Topic; Disease Models; Animal; Eryt; Humans; Neuroprotective Agents; Randomized Controlled Trials as Topic; Recombinant Proteins; Subarachnoid Hemorrhage; Time Factors; hropoietinBrain IschemiaBrain ischemialawmedicineAnimalsHumansClinical TrialsRandomized Controlled Trials as TopicSettore MED/27 - Neurochirurgiabusiness.industryAnimalPhase II as TopicGeneral MedicinehropoietinSubarachnoid Hemorrhagemedicine.diseaseRecombinant ProteinsNeuroprotective AgentsErythropoietinDisease ModelsRecombinant DNAbusinessmedicine.drug
researchProduct

The Blood–Brain Barrier as a Target in Traumatic Brain Injury Treatment

2014

Traumatic brain injury (TBI) is one of the most frequent causes of death in the young population. Several clinical trials have unsuccessfully focused on direct neuroprotective therapies. Recently immunotherapeutic strategies shifted into focus of translational research in acute CNS diseases. Cross-talk between activated microglia and blood–brain barrier (BBB) could initiate opening of the BBB and subsequent recruitment of systemic immune cells and mediators into the brain. Stabilization of the BBB after TBI could be a promising strategy to limit neuronal inflammation, secondary brain damage and acute neurodegeneration. This review provides an overview on the pathophysiology of TBI and brain…

Pathologymedicine.medical_specialtyTraumatic brain injuryPeroxisome Proliferator-Activated ReceptorsBrain EdemaInflammationBrain damageBlood–brain barrierNeuroprotectionRosiglitazoneReceptors GlucocorticoidmedicineHumansHypoglycemic AgentsMyosin-Light-Chain KinaseNeuroinflammationInflammationPioglitazoneMicrogliabusiness.industryNeurodegenerationNeurodegenerative DiseasesGeneral Medicinemedicine.diseaseCell HypoxiaNeuroprotective Agentsmedicine.anatomical_structurenervous systemBlood-Brain BarrierBrain InjuriesThiazolidinedionesmedicine.symptombusinessNeuroscienceArchives of Medical Research
researchProduct

Cardiovascular and Cardioprotective Agents in 2021

2021

Pharmacology2019-20 coronavirus outbreakCardiotonic AgentsCoronavirus disease 2019 (COVID-19)business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Cardiovascular AgentsPharmacologyCardiovascular SystemCardiovascular DiseasesDrug DiscoveryCardiovascular agentHumansMedicineCardioprotective AgentbusinessCurrent Pharmaceutical Design
researchProduct

The many faces of erythropoietin: from erythropoiesis to a rational neuroprotective strategy

2008

It has been more than 10 years since the discovery that erythropoietin (EPO) and its receptor are expressed by the nervous system. In that brief time, a remarkable acceleration in understanding the...

PharmacologyNervous systembusiness.industrySettore MED/27 - NeurochirurgiaGeneral MedicineNeuroprotectionRecombinant ProteinsNeuroprotective Agentsmedicine.anatomical_structureErythropoietinhemic and lymphatic diseasesReceptors ErythropoietinmedicineAnimalsHumansErythropoiesisErythropoietin neuroprotectionPharmacology (medical)ReceptorbusinessErythropoietinNeurosciencemedicine.drug
researchProduct

Editorial (Thematic Issue: Current and Perspective Therapeutic Strategies for Alzheimer's Disease).

2016

PharmacologyPsychotherapistNeuroprotective AgentsAlzheimer DiseaseDrug DiscoveryPerspective (graphical)MEDLINEHumansDiseasePsychologyCurrent pharmaceutical design
researchProduct

Therapeutic potential of dietary polyphenols against brain ageing and neurodegenerative disorders

2010

In recent years there has been a growing interest, supported by a large number of experimental and epidemiological studies, in the beneficial effects of some commonly used food-derived products in preventing various age-related pathologic conditions, ranging from cancer to neurodegenerative diseases. Spices and herbs often contain active phenolic substances endowed with potent antioxidative and chemopreventive properties. Curcumin is a phytochemical compound extracted from the rhizome of Curcuma Longa. It is the pigment responsible for the characteristic yellow color of Indian curry. Data from our and other laboratories demonstrated that curcumin, as well as some other polyphenols, strongly…

PolyphenolAgingCurcuminNeuroprotective AgentDiseasePharmacologyAntioxidantsCatechinchemistry.chemical_compoundCaffeic AcidsPhenolsCellular stress responseMedicineCurcumaAntioxidants; Caffeic Acids; Catechin; Curcumin; Flavonoids; Neuroprotective Agents; Phenols; Phenylethyl Alcohol; Polyphenols; Aging; Brain; Diet; Neurodegenerative DiseasesFlavonoidsbiologyPhenolbusiness.industryPolyphenolsBrainNeurodegenerative DiseasesPhenylethyl Alcoholbiology.organism_classificationDietHeme oxygenaseNeuroprotective AgentschemistryPhytochemicalCaffeic AcidAgeingPhase II DetoxificationCurcuminFlavonoidAntioxidantbusiness
researchProduct

Preservation of Microbial Strains in the Wine Industry

2011

Publisher Summary This chapter provides a general description of the most commonly used methods for the preservation of microbial strains. Long-term preservation methods are considered the most appropriate option wherever possible, since they involve stopping the growth of the microbial cells and keeping them in a viable state. This guarantees maximum genetic stability by preventing the appearance of successive generations. Nevertheless, the possibility that the preparation method itself leads to changes cannot be ruled out. There are two preservation methods belonging to this group: freezing and lyophilization. In the first long-term preservation method, the cells are frozen suspended in a…

Preservation methodsbusiness.industryChemistryGenetic stabilityMicroorganismCryoprotective AgentFree waterSublimation (phase transition)Liquid mediumFood sciencebusinessBiotechnologyWine industry
researchProduct

Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126).

1997

Flupirtine, trade name Katadolon, is a centrally acting nonopioid analgesic that has recently been found to display cytoprotective activity in vitro and in vivo on neurons induced to undergo apoptosis. This report shows that the PrP106-126 fragment of the prion protein, which is the likely etiological agent for a series of encephalopathies, is toxic to cortical neurons in vitro. Simultaneously, PrP106-126 influences the molecular GSH content and the bcl-2 expression in neurons. Significant toxicity (32% reduction in cell viability) was observed at a concentration of 50 microM of the peptide after 9 days of incubation, while at higher concentrations toxicity increased to 70%. Neurotoxicity w…

PrionsMolecular Sequence DataAminopyridinesApoptosisPharmacologyBiologychemistry.chemical_compoundDevelopmental NeurosciencemedicineAnimalsAmino Acid SequenceRats WistarCytotoxicityCells CulturedNeuronsNeurotoxicityGlutathioneAnalgesics Non-Narcoticmedicine.diseaseGlutathioneIn vitroPeptide FragmentsGenes bcl-2RatsOxidative StressNeuroprotective AgentsNeurologychemistryGene Expression RegulationProto-Oncogene Proteins c-bcl-2ApoptosisCell cultureImmunologyToxicityFlupirtineOxidation-Reductionmedicine.drugExperimental neurology
researchProduct